Welcome to our dedicated page for Imunon SEC filings (Ticker: IMNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Imunon, Inc. filings document a Nasdaq-listed clinical-stage biotechnology issuer with common stock trading under IMNN and a business centered on non-viral DNA-mediated immunotherapy. The company's 8-K reports include financial results, business updates, clinical-program disclosures for IMNN-001 and the OVATION studies, and corporate events affecting executive roles and compensation arrangements.
Proxy and registration-related filings describe annual meeting matters, board and executive compensation governance, common-stock capital structure, and at-the-market equity offering arrangements. The filing record also includes Nasdaq listing-compliance disclosures and other public-company status reports tied to Imunon's financing, governance, and clinical-development operations.
Lindborg Stacy reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. executive Stacy Lindborg, President and CEO, received an equity award of 6,615 shares of common stock on 2026-08-14. The shares were valued at $1.65 per share and were granted in lieu of cash for a portion of base salary. Following this grant, Lindborg directly holds 93,254 shares of Imunon common stock and indirectly holds an additional 778 shares through a 401(k) plan.
Faller Douglas Vincent reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. reported that Chief Medical Officer Douglas Vincent Faller received a grant of 3,516 shares of common stock on 2026-08-14. The shares were valued at $1.65 per share and were granted in lieu of cash for a portion of his base salary, bringing his direct holdings to 33,451 shares.
Tardugno Michael H reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. reporting person Michael H. Tardugno, Executive Chairman of the Board, received a grant of 7,147 shares of Common Stock on 2026-08-14. The grant was stock issued in lieu of cash for base salary, increasing his directly held position to 82,504 shares. He also reports 4,622 shares held indirectly through an IRA.
Imunon, Inc. executive Susan Eylward, General Counsel and Corporate Secretary, reported two transactions in Imunon common stock. On August 14, 2026, she acquired 2,449 shares as stock granted in lieu of cash for a portion of base salary at an indicated value of $1.65 per share. On August 17, 2026, she sold 2,449 shares in an open-market or private transaction at a weighted average price of $1.6303 per share, with individual sale prices ranging from $1.61 to $1.655 per share. Post-transaction share holdings are not stated in this report.
Imunon, Inc. is reported to have 450,315 shares of its common stock beneficially owned by Armistice Capital, LLC and Steven Boyd, who together are the reporting persons. This represents 9.99% of Imunon’s outstanding common stock.
Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and exercises voting and investment power over these securities under an Investment Management Agreement. Steven Boyd, as managing member of Armistice Capital, may be deemed to share beneficial ownership. The Master Fund has the right to receive dividends and sale proceeds for the reported securities.
Imunon, Inc. approved new stock-based compensation elections for senior executives, allowing part of their base salaries to be paid in common stock instead of cash. The President and Chief Executive Officer, Stacy Lindborg, may receive up to 50% of base salary in shares, with additional shares equal to 12% of the aggregate dollar amount of the net stock payment, amended to 35% for shares issuable on August 14 and to 17.5% for shares issuable on each pay date from August 28, 2026 through September 25, 2026. Executive Chairman Michael Tardugno may elect up to 100% of base salary in shares, with additional shares equal to 20% for July 31 issuances, 40% for August 14, and 20% for each pay date from August 28, 2026 through September 25, 2026. Chief Medical Officer Douglas Faller may elect up to 40% of base salary in shares, with additional shares equal to 12% of the net stock payment, amended to 15% for each pay date from July 31, 2026 through September 25, 2026. Shares for Dr. Lindborg and Mr. Tardugno are treated as private offerings under Section 4(a)(2) of the Securities Act, while shares for Dr. Faller will be issued under the Imunon, Inc. 2018 Stock Incentive Plan.
Imunon, Inc. reported a continuing net loss and heightened financial risk for the six months ended June 30, 2026. The company recorded a net loss of $7.1 million, slightly higher than the $6.8 million loss a year earlier, driven by $3.8 million in research and development expenses and $3.3 million in general and administrative costs.
Liquidity remains strained. Unrestricted cash and cash equivalents were $6.9 million, with an additional $5.0 million held as restricted cash, mainly as collateral for new debt, bringing total assets to $15.0 million. Operating activities used $7.0 million of cash in the first half, while financing activities provided $10.2 million, including equity sales and a June 2026 transaction with Streeterville Capital comprising $2.5 million of Series A preferred stock and secured notes totaling $7.7 million.
The company now carries $10.8 million in total liabilities, including Notes A and B and a derivative liability related to a redemption feature on Note A. Management explicitly concludes that recurring losses, limited cash, and funding needs raise substantial doubt about Imunon’s ability to continue as a going concern, absent additional capital raises, collaborations, or other strategic transactions.
Imunon, Inc. reported financial results for the three and six months ended June 30, 2026 and highlighted progress in its lead DNA-based immunotherapy IMNN-001 for newly diagnosed advanced ovarian cancer. Management reported that enrollment in the pivotal Phase 3 OVATION 3 study is exceeding planning assumptions and is supported by prior Phase 2 data showing a clinically meaningful overall survival benefit. New preliminary data from an ongoing Phase 2 minimal residual disease study showed deeper antitumor responses, including higher circulating tumor DNA clearance and no evidence of disease following frontline therapy in treated patients.
For the second quarter of 2026, net loss was $2.8 million, or $0.54 per share, with operating expenses of $2.8 million. For the first half of 2026, net loss was $7.1 million, or $1.38 per share, on operating expenses of $7.1 million. Research and development expenses increased while general and administrative expenses declined versus 2025. Net cash used in operating activities for the first half of 2026 was $7.0 million, and cash and cash equivalents were $6.9 million as of June 30, 2026, with total liabilities of $10.8 million and stockholders’ equity of $4.2 million.
Pellizzari Christine A reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. director Christine A. Pellizzari received a grant of 6,934 shares of common stock on July 31, 2026, at a stated value of $1.59 per share. The shares were granted in lieu of cash for a portion of her board fees, bringing her direct holdings to 15,076 shares.
Dentzer James E reported acquisition or exercise transactions in this Form 4 filing.
Imunon, Inc. reported that director James E. Dentzer received a grant of 6,934 shares of common stock on July 31, 2026, as a stock grant in lieu of cash for a portion of his board fees at an indicated value of $1.59 per share. Following this award, he directly holds 21,897 shares of Imunon common stock.